-transparent.png){kind=logo}
A fluoroimmunoassay has been developed for the simultaneous determination of serum levels of procainamide and its active metabolite N-acetylprocainamide. It employs procainamide linked through its aromatic amino group to fluorescein isothiocyanate as tracer and an antiserum raised against procainamide conjugated to human thyroglobulin through the same position. Separation is rapidly and simply achieved by covalently linking the antiserum to magnetisable microparticles and use of a magnet. Specific magnetisable particle fluorimmunoassays were also developed for procainamide and for N-acetylprocainamide by the use of suitable immunogens and fluorescein-labelled tracers. That for procainamide uses an antiserum raised to a procainamide-enzyme conjugate and fluorescein-labelled p-aminobenzoic acid while the fluoroimmunoassay for N-acetylprocainamide employs an antiserum against a N-acetylprocainamide-enzyme conjugate and fluorescein-labelled p-acetamidobenzoic acid.
M H Al-Hakiem, and
D S Smith, and
J Landon
May 1984,
Clinical chemistry,
M H Al-Hakiem, and
D S Smith, and
J Landon
June 1983,
Therapeutic drug monitoring,
M H Al-Hakiem, and
D S Smith, and
J Landon
October 1983,
Journal of chromatography,
M H Al-Hakiem, and
D S Smith, and
J Landon
January 1982,
Journal of analytical toxicology,
M H Al-Hakiem, and
D S Smith, and
J Landon
June 1988,
Yao xue xue bao = Acta pharmaceutica Sinica,
M H Al-Hakiem, and
D S Smith, and
J Landon
December 1981,
Clinical chemistry,
M H Al-Hakiem, and
D S Smith, and
J Landon
March 1987,
Journal of chromatography,
M H Al-Hakiem, and
D S Smith, and
J Landon
January 1981,
Therapeutic drug monitoring,
M H Al-Hakiem, and
D S Smith, and
J Landon
March 1981,
Journal of pharmaceutical sciences,
M H Al-Hakiem, and
D S Smith, and
J Landon
June 1974,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
